Final Thoughts on the Future of Liver Cancer
A panel of experts lead by Richard S. Finn, MD, provide their final thoughts on the future of advanced unresectable liver cancer.
Challenges of Sequencing and Biomarkers in Hepatocellular Carcinoma
Experts provide insight into the challenges of sequencing and biomarkers when treating advanced HCC.
Role of Single Agent IO in Hepatocellular Carcinoma Frontline Therapies
A summary of ongoing clinical data that explore the use of frontline single agent immunotherapy in advanced HCC.
HCC Treatment: Emerging Data in IO Combinations
Experts discuss emerging data in immunotherapy combination approaches for the treatment of advanced HCC.
Ongoing Data for First-line Combinations in HCC
A summary of updates that explore ongoing data from various frontline combinations in unresectable HCC.
Role of TKIs in HCC Treatment
An examination of the use of second-line therapies after atezolizumab-bevacizumab, and the role of TKIs for the treatment of advanced HCC.
Treatment Strategies for Childs-Pugh B Disease
Experts expand on treatment strategies and sequencing approaches used for Child-Pugh B liver disease.
Considerations for Later Lines of Therapy in HCC Treatment
Experts in the field of HCC consider second and third lines of therapy after a patient’s disease state progresses after frontline atezolizumab-bevacizumab.
Personal Experience Using Atezolizumab-Bevacizumab in HCC Treatment
Laura M. Kulik, MD, leads a discussion about personal experiences using atezolizumab-bevacizumab and whether clinical trial data reflect real-world experience.
A New Standard of Care for Liver Cancer Treatment
A discussion about the recent data from trials that looked at atezolizumab-bevacizumab for the treatment of advanced HCC, and its role as the new standard of care.
Combination Therapy for HCC Treatment
Experts discuss recent data surrounding emerging combinations of TACE plus systemic therapies for patients with BCLC stage B or C HCC.
TACE and Systemic Therapy in HCC
An in-depth discussion about the role of TACE in combination with systemic therapies for the treatment of HCC.
Recent Findings in Systemic Therapy for Patients With BCLC Stage B HCC
Amit G. Singal, MD, MS, leads a review of recent data around the outcomes of systemic therapy for patients with BCLC stage B HCC.
Practical Considerations of TACE in HCC
A panel of experts discuss practical considerations for TACE in patients with unresectable BCLC stage B HCC, as well as define TACE-refractoriness and what to do if a patient fails treatment.
Management Challenges of Advanced HCC
Richard S. Finn, MD, leads a panel of experts in a discussion around key updates from the 2021 ASCO GI virtual meeting, and a review of the rapidly evolving landscape for unresectable advanced hepatocellular carcinoma.
Later-Line Ruxolitinib Use Produces Ongoing Benefit in Real-World Patients With cGVHD
Orca-T Data With Survival, Tolerability Extends to Older Patients With Hematologic Cancers
Dr Ramdial on Gemcitabine/Clofarabine/Busulfan for Lymphoma Stem Cell Transplant
Retrospective Analysis Shows Post-HCT Survival Benefits With Orca-T Vs PTCy in Hematologic Malignancies
2 Commerce Drive Cranbury, NJ 08512